JP2022520596A5 - - Google Patents
Info
- Publication number
- JP2022520596A5 JP2022520596A5 JP2021547322A JP2021547322A JP2022520596A5 JP 2022520596 A5 JP2022520596 A5 JP 2022520596A5 JP 2021547322 A JP2021547322 A JP 2021547322A JP 2021547322 A JP2021547322 A JP 2021547322A JP 2022520596 A5 JP2022520596 A5 JP 2022520596A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805291P | 2019-02-13 | 2019-02-13 | |
| US62/805,291 | 2019-02-13 | ||
| PCT/US2020/018160 WO2020168110A1 (en) | 2019-02-13 | 2020-02-13 | Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022520596A JP2022520596A (ja) | 2022-03-31 |
| JPWO2020168110A5 JPWO2020168110A5 (https=) | 2023-02-21 |
| JP2022520596A5 true JP2022520596A5 (https=) | 2023-02-21 |
Family
ID=72045655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547322A Pending JP2022520596A (ja) | 2019-02-13 | 2020-02-13 | 前立腺がんを治療するための新規マーカーとしてのｅｐｈｂ４－エフリンｂ２受容体リガンド対 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220153791A1 (https=) |
| EP (1) | EP3923969A4 (https=) |
| JP (1) | JP2022520596A (https=) |
| KR (1) | KR20220010469A (https=) |
| CN (1) | CN114007633A (https=) |
| AU (1) | AU2020221276A1 (https=) |
| CA (1) | CA3139416A1 (https=) |
| WO (1) | WO2020168110A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021012208A (es) | 2013-10-04 | 2023-01-19 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos. |
| NZ724368A (en) | 2014-03-19 | 2023-07-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| EP4585268A3 (en) | 2015-09-14 | 2025-10-15 | Twelve Therapeutics, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| WO2020190977A1 (en) * | 2019-03-17 | 2020-09-24 | Vasgene Therapeutics Inc | Treatment of cancers using sephb4-hsa fusion proteins |
| CA3211742A1 (en) * | 2021-03-18 | 2022-09-22 | Valery Krasnoperov | Use of sephb4-hsa fusion protein as a first-line therapy in cancer treatment |
| CN118290563B (zh) * | 2024-06-03 | 2024-08-02 | 磐如生物科技(天津)有限公司 | 一种前列腺癌抗原肽和免疫佐剂组合物及其在抗肿瘤中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7381410B2 (en) * | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| EP1778726A4 (en) * | 2004-08-16 | 2009-03-18 | Medimmune Inc | INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY |
| WO2006034455A2 (en) * | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Polipeptide compounds for inhibiting angiogenesis and tumor growth |
| WO2012068477A1 (en) * | 2010-11-19 | 2012-05-24 | Vasgene Therapeutics, Inc. | Methods and compositions for inhibiting angiogenesis and tumor growth |
| EP2922861A4 (en) * | 2012-11-26 | 2016-09-14 | Caris Life Sciences Switzerland Holdings Gmbh | BIOMARKER COMPOSITIONS AND METHODS |
| WO2020190977A1 (en) * | 2019-03-17 | 2020-09-24 | Vasgene Therapeutics Inc | Treatment of cancers using sephb4-hsa fusion proteins |
-
2020
- 2020-02-13 CA CA3139416A patent/CA3139416A1/en active Pending
- 2020-02-13 EP EP20756368.5A patent/EP3923969A4/en not_active Withdrawn
- 2020-02-13 CN CN202080028627.1A patent/CN114007633A/zh active Pending
- 2020-02-13 AU AU2020221276A patent/AU2020221276A1/en not_active Abandoned
- 2020-02-13 JP JP2021547322A patent/JP2022520596A/ja active Pending
- 2020-02-13 KR KR1020217029023A patent/KR20220010469A/ko not_active Ceased
- 2020-02-13 US US17/430,186 patent/US20220153791A1/en not_active Abandoned
- 2020-02-13 WO PCT/US2020/018160 patent/WO2020168110A1/en not_active Ceased